[1,7]naphthyridines as PDE4 inhibitors
US7468370B2 · kind B2 · utility
4Cited by
0References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 15, 2003 |
| Grant date | Dec 23, 2008 |
| Priority date | — |
| Expiry date | Nov 8, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of formula Iin free or salt form, wherein R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by of phosphodiesterase type 4 or the down-regulation or inhibition of TNF-α release, particularly obstructive or inflammatory airways diseases. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.